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Abstract: Anemia has an unfavorable impact on quality of life in chronic lymphocytic 
l  eukemia (CLL), increases the likelihood of receiving blood transfusions, and eventually has 
a negative impact on overall survival. Although discrepancies in perception of health-related 
quality of life between doctors and patients lead to the undertreatment of anemia, CLL patients 
undergoing chemotherapy who have a hemoglobin level ,10 g/dL should be considered for 
treatment with erythropoiesis-stimulating agents. For hemoglobin values of 10–12 g/dL, the 
role of performance status and comorbidities should not be underestimated. In this setting, the 
evaluation of physical fitness using the Cumulative Illness Rating Scale should help physicians 
to identify those patients with hemoglobin levels of 10–12 g/dL who are suitable for therapy 
with erythropoiesis-stimulating agents. Finally, the increasing use of aggressive approaches 
to therapy should encourage physicians towards appropriate management of chemotherapy-
induced anemia in CLL patients.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia 
in Western countries, with an annual incidence of 2–4.5 per 100,000 new cases.1 The 
disease is twice as common in men as it is in women, and affects mostly the elderly, 
with the median age at diagnosis being 73 years. After decades of remaining static, the 
management of LLC is now rapidly evolving. The introduction of purine   analogs, fol-
lowed by monoclonal antibodies, has revitalized clinical research in CLL.   Furthermore, 
autologous hematopoietic stem cell transplantation is a feasible option, with low 
treatment-related mortality, although there are questions relating to optimal timing of the 
procedure, the conditioning regimen, and late effects.2–7 A series of biomarkers including 
CD38, immunoglobulin, mutational status, zeta chain-associated protein kinase 70, and 
cytogenetics, as well as TP53 mutations, have improved the prognostic evaluation of 
patients with CLL and helped to identify risk-adapted treatment programs.8,9
Despite these achievements, the results of recent clinical trials have shown a 
limited impact on overall survival. Therefore, in this context, it is important to ensure 
an adequate quality of life for patients.10 The changes in quality of life for patients 
with CLL are closely related to the degree of anemia, although duration of disease, 
type and intensity of chemotherapy, and intercurrent infection have an important 
role.11 This review deals with the pathogenesis, clinical significance, and treatment of 
  nonautoimmune hemolytic anemia in patients with CLL. We also attempt to provide 
useful practical support for day-by-day clinical practice.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Incidence of anemia
Although an increasing number of patients with CLL are 
now diagnosed at an early stage of disease, the results of a 
recent monoinstitutional study, which analyzed changes in 
the pattern of disease presentation over the last 30 years, indi-
cate that the incidence of anemia ranges between 5%–6%.12 
  Anemia in CLL may also be secondary to chemotherapy or 
chemoimmunotherapy, and combinations of fludarabine, 
cyclophosphamide, and rituximab induce anemia, with a 
frequency ranging between 5.4% and 24% in relation to use 
in untreated or previously treated patients.13,14 Finally, CLL 
patients may develop autoimmune hemolytic anemia, with 
a rate ranging between 2.9% for stable Binet stage A and 
10.5% for Binet stages B and C.15
Pathogenesis of nonautoimmune  
hemolytic anemia
The pathogenesis of nonautoimmune hemolytic anemia in 
CLL is a relatively unaddressed issue. Recently, Tsopra et al16 
in a study involving 56 CLL patients established that bone 
marrow infiltration was not the only factor responsible 
for anemia. In addition, CD34-positive cells were able to 
generate erythroid precursors, while circulating levels of 
erythropoietin were within the normal range. In the same 
patient cohort, it was also found that serum levels of tumor 
necrosis factor-alpha (TNF-α) were higher in patients with 
anemia, and the addition of TNF-α inhibited erythroid growth 
in the early stages of erythropoiesis.16 These results led to the 
conclusion that CLL-related anemia is not an expression of an 
intrinsic defect of erythroid precursors, but the result of direct 
suppression of erythropoiesis by TNF-α. Figure 1 shows 
the pathway for differentiation of erythroid progenitors into 
mature red blood cells. The progenitors express receptors for 
the inflammatory cytokines necessary for normal differen-
tiation into red blood cells, but, in conditions of absolute or 
relative deficiency of erythropoietin, these cytokines facilitate 
erythrocyte death. This model is designed to explain the 
pathogenesis of anemia in patients with solid tumors, and 
may also be used to elucidate mechanisms underlying the 
development of anemia in CLL.17
Consequences of anemia
Anemia plays an important role in promoting the angiogenic 
processes involved in the progression of CLL, whereby 
altered tissue oxygenation secondary to anemia leads to 
exaggerated production of angiogenic cytokines (vascular 
endothelial growth factor, basic fibroblast growth factor) by 
either leukemic or bone marrow microenvironment cells.18 
Different studies have demonstrated an increase of bone 
marrow microvessels, as well as higher circulating levels of 
vascular endothelial growth factor, correlate with biologi-
cal features of poor prognosis19 (Figure 2). From a clinical 
standpoint, anemia in patients with CLL has an unfavorable 
impact on the quality of life, increases the likelihood of 
receiving blood transfusions, and eventually has a negative 
impact on overall survival.20,21
The changes in parameters related to quality of life 
can be underestimated in patients with CLL.10 The results 
of the prospective LFR Chronic Lymphocytic Leukaemia 
Trial 4 highlight the role of anemia in determining clini-
cally meaningful changes in quality of life, especially when 
associated with a higher tumor burden and progressive 
disease.11
Anemia is an independent risk factor related to higher 
incidence of complications from chemotherapy. Most anti-
neoplastic agents bind to red blood cells, so the increased 
concentration of free drug in the bloodstream strengthens 
the risk of toxicity in anemic CLL patients.20 Finally, the 
importance of anemia as a prognostic factor is supported by 
the negative correlation between low hemoglobin levels and 
reduced survival. Hemoglobin concentrations ,10–11 g/dL 
define a subgroup of patients at high risk both in the Rai 
(ie, stage III) and Binet (ie, stage C) classifications.22,23 
  Importantly, patients with advanced (ie, Binet stage C) 
disease due to an autoimmune mechanism had significantly 
better survival than those in an advanced stage related to 
massive bone marrow infiltration (median survival 7.4 years 
versus 3.7 years, P = 0.02).24 These results emphasize the 
importance of determining the origin of anemia and/or 
thrombocytopenia in patients with CLL, for both treatment 
and prognostic purposes.
Use of erythropoietin in CLL
Although most clinical studies of erythropoiesis-stimulating 
agents have included patients with epithelial cancers, there 
is clear evidence, supported by the results of meta-analysis, 
that their efficacy is similar in hematologic malignancies.25 
The major advantage of erythropoiesis-stimulating agents 
over blood transfusions has been the maintenance of con-
sistent hemoglobin levels, as well as the reduction in risk of 
transfusion-related immunomodulation.25
Among the different erythropoiesis-stimulating agents, 
epoietin has been the most widely used in the treatment of 
patients with CLL26–29 (see Table 1). In a prospective, dou-
ble-blind trial, 221 anemic CLL patients were   randomized 
to receive epoetin alfa 150 U/kg or placebo three Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 1 Differentiation of erythroid progenitors to mature red blood cells. As shown, the progenitors express receptors for the inflammatory cytokines necessary for 
normal differentiation into red blood cells, but, in conditions of absolute or relative deficiency of erythropoietin, these cytokines facilitate erythrocyte death.
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times weekly. Treatment with epoetin alfa led to an increase 
in hematocrit values by .6% in 50% of treated patients. 
This study also showed that the increased hemoglobin levels 
translated into an improvement in quality of life.26 In a dose-
escalation trial, epoetin alfa was administered at an initial 
dose of 150 U/kg three times per week. In nonresponders, 
the dose was gradually increased to a maximum of 300 U/
kg. A complete response (final hematocrit .38%) was 
observed in 55% of patients, and a partial response (increase 
in hematocrit $ 6%) in 33% of patients. In the same study, 
a role of maintenance therapy using epoetin alfa 150 U/kg 
per week on duration of response was demonstrated.27
In a placebo-controlled trial that included patients 
with multiple myeloma and non-Hodgkin’s lymphoma, 
Osterborg et al28 treated 126 CLL patients with transfusion-
dependent anemia and low levels of erythropoietin. In this 
study, the primary endpoint of which was the transfusion-
free interval between the fifth and sixteenth week after   
initiation of therapy with epoetin beta, the risk of needing 
a blood transfusion was reduced by 40% in patients treated 
with epoetin beta compared with controls.
Pangalis et al29 assessed the efficacy of recombinant 
erythropoietin in 25 patients with CLL in Rai stage III, with 
the idea that treatment of anemia could translate into a delay 
in the start of chemotherapy and/or into possible advantage 
for overall survival. Treatment with recombinant erythropoi-
etin produced a complete response (increase in hematocrit 
value . 38%) in 18 of 25 patients and a partial response 
(increase greater than 6% of hematocrit values but, 
overall, ,38%) in two patients. In addition, 19 patients 
obtained a downstaging of disease, with a change to Rai 
stage 0 in six patients and to Rai stage I–II in 13 patients. 
After a median follow-up of 32 months, only four patients 
needed antileukemic treatment, and survival rates projected 
at three years were 84%. Although the results reported by 
Pangalis et al29 appear interesting, further clinical trials are 
needed to determine whether recombinant erythropoietin 
has any impact on the outcome of disease and whether this 
effect translates into a survival benefit.
CLL cells and erythropoietin  
receptors
There has been intense debate in the scientific community 
recently concerning the possibility that recombinant eryth-
ropoietin may have a role in the mechanism of tumor pro-
gression. On the other hand, the results of two prospective, 
placebo-controlled studies showed that patients with head 
and neck and breast cancer treated with erythropoietin had 
a worse clinical outcome compared with controls.30,31 Eryth-
ropoietin is currently used to treat chemotherapy-induced 
anemia in patients with lymphoproliferative disorders. 
However, information on the expression of erythropoietin 
receptors by tumor cells is limited. Kokhaei et al32 recently 
reported the results of a group of CLL patients analyzed for 
either the expression of erythropoietin receptors or the effects 
on leukemic cells induced by different erythropoiesis-stimu-
lating agents in vitro. Despite the presence of erythropoietin 
receptor mRNA, the corresponding membrane protein was 
never identified, and it was not possible to document the 
phenomena of activation or cell proliferation after stimula-
tion with CD40L-transfected fibroblasts. These results sug-
gest that erythropoiesis-stimulating agents can be used with 
reasonable safety in patients with CLL and anemia related to 
chemotherapy. However, physicians should refer to current 
guidelines, and consider the benefits and risks associated 
with use of erythropoiesis-stimulating agents. From a clinical 
standpoint, a recent meta-analysis including 12 randomized 
studies, including a total of 2297 patients with solid tumors 
or nonmyeloid hematological malignancies, demonstrated 
that epoetin beta does not have any impact on survival or 
tumor progression.33
Recommendations for use of  
erythropoietic growth factors
A panel of international experts was convened in June 1999 in 
Barcelona to make recommendations for the optimal use 
of erythropoiesis-stimulating agents in CLL and   multiple 
  myeloma.34 Many observations made at this consensus 
  conference are part of the recently updated American   Society 
Table 1 Studies of erythropoietin in chronic lymphocytic leukemia
Author Patients 
(n)
Erythropoietin Type of study Response 
rate (%)
Improvement in   
quality of life
Rose et al26 221 ePO-α Phase ii  
(placebo-controlled)
50% Yes
Siakantaris et al27 22 ePO-α Phase ii (dose- escalation) 88% No
österborg et al28 126 ePO-β Phase iii (placebo-controlled) 63%  Yes
Pangalis et al29  25  ePO-α Phase ii (pilot) 80% Not available
Abbreviation: ePO, erythropoietin.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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of Hematology/American Society of Clinical Oncology 
guidelines,25,35,36 the important points of which are summa-
rized below.
Treatment of CLL-related anemia should be directed 
to the deferral or reduction of transfusion requirements 
and improvement in quality of life. The use of antileuke-
mic treatment and evaluation of its effectiveness should 
precede the use of erythropoiesis-stimulating agents. After 
2–3 cycles of chemotherapy or chemoimmunotherapy, 
in the absence of a hemoglobin increase, treatment with 
erythropoiesis-stimulating agents should be considered 
in agreement with American Society of Hematology/
American Society of Clinical Oncology guidelines.25,35,36 A 
systematic review of literature based on 40 studies includ-
ing 21,376 patients showed that the clinical benefits and 
risks associated with the use of erythropoiesis-stimulating 
agents do not differ according to the use of epoetin or   
darbepoetin.37
Treatment with erythropoiesis-stimulating agents is 
generally recommended for all patients with CLL and hemo-
globin ,10 g/dL. For hemoglobin values in the 10–12 g/dL 
range, the role of performance status and comorbidities 
should not be underestimated. For instance, a Cumulative 
Illness Rating Scale .6 in patients older than 65 years should 
prompt physicians to consider treatment with erythropoiesis-
stimulating agents.13 Also, the presence of cardiac comor-
bidity in the elderly should be considered an indication for 
starting erythropoiesis-stimulating agents in patients with 
hemoglobin levels ,12 g/dL. Recombinant erythropoietin 
protects cardiomyocytes from hypoxic damage leading to 
apoptosis, and a Phase III clinical trial has recently been 
initiated to clarify the effects of recombinant erythropoietin 
on the outcome in patients with chronic heart failure.38 The 
aim of treatment with erythropoiesis-stimulating agents is to 
achieve a hemoglobin level of 12 g/dL, using an initial dose 
of 40,000 U of epoetin once a week. This dose and adminis-
tration schedule have proved to be as effective as 10,000 U 
three times a week.25,35,36
Lack of response to therapy is defined as an increase in 
hemoglobin of ,1 g/dL after at least four weeks of treat-
ment with erythropoiesis-stimulating agents. If the patient is 
receiving 10,000 IU of epoetin three times a week, the dose 
may be doubled. In the event of no response to the weekly 
dose of 40,000 IU, a dose increase to 60,000 IU once a week 
is recommended. A lack of response after an increased dose 
should prompt the clinician to consider the patient refractory 
to erythropoiesis-stimulating agents and to consider condi-
tions responsible for failure.25,35,36 For example, a diagnosis 
of autoimmune hemolytic anemia should not be ruled out. 
Therefore, a diagnosis of autoimmune hemolytic anemia, 
expecially in patients who are receiving fludarabine as a 
single agent, should be ruled out.15 The subgroup of patients 
who reach a hemoglobin level .12 g/dL but ,14 g/dL may 
be considered for maintenance erythropoietin, administered 
at two-weekly intervals.
Finally, CLL patients treated with lenalidomide are 
candidates to receive erythropoiesis-stimulating agents, 
and represent a subgroup at high risk of thromboembolic 
episodes.39 Although there are no defined risk factors for 
thromboembolism in patients with CLL, clinicians should 
exercise caution with concomitant use of erythropoietic 
growth factors and lenalidomide.
Conclusion
Anemia in CLL is associated with decreased survival, 
reduced quality of life, increased risk of chemotherapy-
related toxicity, and increased use of blood transfusions.40 
  Erythropoiesis-stimulating agents have an important 
advantage over blood transfusions in the treatment of CLL-
related anemia.25,35,36 However, they should be avoided in 
patients with CLL not receiving concurrent chemotherapy. 
For patients undergoing chemotherapy who have a hemo-
globin level ,10 g/dL, clinicians should discuss potential 
risks (eg, thromboembolism, shorter survival) and benefits 
(eg, decreased transfusions) of erythropoiesis-stimulating 
agents, and balance these with the potential risks (eg, seri-
ous infections, immune-mediated adverse reactions) and 
benefits (eg, rapid hemoglobin improvement) of red blood 
cell transfusion.25,35,36 Individual preferences for assumed 
risk should contribute to the shared decision-making in the 
management of chemotherapy-induced anemia. If used, 
erythropoiesis-stimulating agents should be administered 
at the lowest dose possible and should increase hemoglobin 
to the lowest concentration possible to avoid transfusions. 
Erythropoiesis-stimulating agents should be discontinued 
after 6–8 weeks in nonresponders. Caution should be exer-
cised when using erythropoiesis-stimulating agents with anti-
leukemic agents (ie, lenalidomide) because of the increased 
risk of thromboembolic complications.
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